Clinical Research Directory

Inclusion Criteria: * BMI \>16 to ≤40 kg/m2; written informed consent. * Symptomatic strictures based on S-PRO2 criteria. * ≤2 small bowel strictures (naïve, native or anastomotic) confirmed by central MRE read; primary lesion is most distal and reachable by ileocolonoscopy. * MRE features consistent with stricture, including: * Luminal narrowing (≥50%). * Bowel wall thickening (≥25%). * Pre-stenotic dilatation (≥25 mm). * Stable background Crohn's therapy after induction with no planned changes for study duration (biologics must be stable for ≥12 weeks prior to screening, with shorter windows for other medication classes as defined in the protocol). * Screening labs and vital signs within protocol-defined limits; pregnancy prevention requirements met. Exclusion Criteria: * Severe disease activity as measured by Crohn's Disease Activity Index (CDAI). * Other colitis diagnoses (e.g. ulcerative, indeterminate, ischaemic, NSAID-induced, microscopic, radiation). * Intestinal dysplasia/malignancy. * Likely to require endoscopic balloon dilation or surgery within 6 months, in the opinion of the investigator. * Received either endoscopic balloon dilation or intestinal surgery within the past 6 months. * Major surgery within 8 weeks pre-randomisation or planned during the study; extensive resections/proctocolectomy; short gut syndrome (≤200 cm small bowel). * Active septic/penetrating complications of CD (e.g., fistulas, abscess, phlegmon), pouches/ostomies, anal/perianal strictures, toxic megacolon, inability to eat, or current hospitalisation for Crohn's disease. * Prohibited concomitant medications; prior RXC008 exposure; recent/concurrent participation in another interventional study (per protocol windows).